Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.48 |
| ▸ | TPI1 | P60174 | 2/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198793 | 0.84 | LPAR3 (0.46) | LPAR3LPAR2LPAR1BTN3A1TPI1 | |
| Isopentenyl Phosphate SCHEMBL545278 | 0.82 | BTN3A1 (0.70) | LPAR3LPAR2LPAR1BTN3A1TPI1 | |
| Isopentenyl Phosphate SCHEMBL28018171 | 0.80 | BTN3A1 (0.68) | LPAR3LPAR2LPAR1BTN3A1TPI1 | |
| SCHEMBL811703 | 0.78 | LPAR3 (0.55) | LPAR3LPAR2LPAR1TPI1PGK1 | |
| SCHEMBL1926070 | 0.77 | BTN3A1 (0.48) | LPAR3LPAR2LPAR1BTN3A1TPI1 | |
| SCHEMBL2710223 | 0.76 | LPAR3 (0.43) | LPAR3LPAR2LPAR1BTN3A1TPI1 | |
| SCHEMBL6514945 | 0.76 | LPAR3 (0.52) | LPAR3LPAR2LPAR1TPI1PGK1 | |
| SCHEMBL16792076 | 0.75 | LPAR3 (0.54) | LPAR3LPAR2LPAR1BTN3A1 | |
| SCHEMBL1514200 | 0.74 | — | — | |
| Propyl Phosphate SCHEMBL28303359 | 0.74 | LPAR3 (0.65) | LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | claimed |
| WO-2021260582-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND AURORA B INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| US-8268841-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-7528121-B2 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1578755-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575966-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004105764-A1 | (3- ((QUINAZOLIN-4-YL) AMINO )-1H-PYRAZOL-1-YL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058782-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | LPAR3 4630/4885LPAR2 4784/4885LPAR1 4763/4885 |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | LPAR3 3136/4885LPAR2 3649/4885LPAR1 3601/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | LPAR3 4605/4885LPAR2 4678/4885LPAR1 4714/4885 |
| US-20100069412-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | LPAR3 3136/4885LPAR2 3649/4885LPAR1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.